NCT07208799 Comparison of Submucosal Dexamethasone and Methylprednisolone in Postoperative Sequelae of Parasymphsis Fractures
| NCT ID | NCT07208799 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Nishtar Medical University |
| Condition | Mandible Fracture |
| Study Type | INTERVENTIONAL |
| Enrollment | 72 participants |
| Start Date | 2026-01-03 |
| Primary Completion | 2026-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 72 participants in total. It began in 2026-01-03 with a primary completion date of 2026-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The rationale of the current research is to address the limitation of existing knowledge as it is not clear which of the two drugs (Dexamethasone or Methylprednisolone) is more effective in reduction of postoperative sequelae in patient with mandibular parasymphysis fracture. This study fills the gap by providing sound evidence on the preferred steroid option to help clinicians have more data to make decisions and improve patients' health. The result of this research will then be added to the evidence-based protocols for the treatment of parasymphysis fractures.
Eligibility Criteria
Inclusion Criteria: 1. Patients aged 18 to 40. 2. Both Gender. 3. Fracture less than a week old. 4. Isolated mandibular parasymphysis fractures. Exclusion Criteria: * 1\. Immunocompromised patients (due to increased risk of infection and complications). 2\. Patients experiencing acute pain from conditions such as pulpitis, abscesses, or other acute infections (to ensure that acute pain does not confound the study results). 3\. Patients reporting hypersensitivity to steroids (to avoid adverse reactions). 4\. Patients taking or requiring prophylactic antibiotics or anti-inflammatory drugs before surgery (to prevent confounding effects on study outcomes). 5\. Patients with a history of systemic steroid administration for 15 days (as this could affect the study's outcomes). 6\. Patients with chronic pain problems or mental disorders (to maintain consistency in response to treatment). 7\. Patients with comminuted fractures (to maintain consistency in fracture type). 8\. Pregnant or lactating women (to avoid potential risks to the fetus and nursing infant). 9\. Smokers who smoke at least 10 cigarettes per day for 2 years (to minimize the impact of smoking on healing and recovery). ria:
Contact & Investigator
Dr amjad ali Bari, M.D.S (OMFS)
STUDY DIRECTOR
NISHTAR INSITUTE OF DENTISTRY, MULTAN
Frequently Asked Questions
Who can join the NCT07208799 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 40 Years, studying Mandible Fracture. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07208799 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07208799 currently recruiting?
Yes, NCT07208799 is actively recruiting participants. Contact the research team at ammaraligoraya@gmail.com for enrollment information.
Where is the NCT07208799 trial being conducted?
This trial is being conducted at Multan, Pakistan.
Who is sponsoring the NCT07208799 clinical trial?
NCT07208799 is sponsored by Nishtar Medical University. The principal investigator is Dr amjad ali Bari, M.D.S (OMFS) at NISHTAR INSITUTE OF DENTISTRY, MULTAN. The trial plans to enroll 72 participants.